Characteristics of two alternative schizophrenia remission definitions: Relationship to clinical and quality of life outcomes

Schizophrenia Research

Volumn 86, Issue 1-3, 2006, Pages 300-308

  Dunayevich, Eduardo ^a   Sethuraman, Gopalan ^a   Enerson, Mark ^a   Taylor, Cindy C ^a   Lin, Daniel ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Antipsychotics; Functional outcomes; Meta analysis; Quality of life; Remission; Schizophrenia

Indexed keywords

ADULT; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DISEASE DURATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGATIVE SYNDROME; POSITIVE SYNDROME; PREDICTION; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION; SCHIZOPHRENIA; STATISTICAL SIGNIFICANCE; SYMPTOM;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TIME FACTORS; TREATMENT OUTCOME;

EID: 33747178942     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2006.06.002     Document Type: Article

References (20)

1. Andreasen N.C., Carpenter Jr. W.T., Kane J.M., Lasser R.A., Marder S.R., and Weinberger D.R. Remission in schizophrenia: proposed criteria and rationale for consensus. Am. J. Psychiatry 162 3 (2005) 441-449
2. Bow-Thomas C.C., Velligan D.I., Miller A.L., and Olsen J. Predicting quality of life from symptomatology in schizophrenia at exacerbation and stabilization. Psychiatry Res. 86 2 (1999) 131-142
3. Breier A., Schreiber J.L., Dyer J., and Pickar D. National Institute of Mental Health longitudinal study of chronic schizophrenia. prognosis and predictors of outcome. Arch. Gen. Psychiatry 48 3 (1991) 239-246
4. Breier A., Young C., Purdon S.E., Gold J.M., Davis K.L., and Keefe R.S.E. A one-year double-blind comparison of the neurocognitive efficacy of olanzaine, risperidone, and haloperidol in patients with schizophrenia. Schizophr Res. 60 1S (2003) 274-275
5. Breier A., Berg P., Thakore J.H., Naber D., Gattaz W.F., Cavazzoni P., Walker D.J., Roychowdhury S.M., and Kane J.M. Olanzapine versus ziprasidone: results of the 28-week double-blind study in Patients With Schizophrenia. Am. J. Psych. 162 10 (2005) 1879-1887
6. Dunayevich E., Zhao F., Ascher-Svanum A., Mitchell C.P., Phillips G.A., Dellva M.A., and Green A. Longer time to all-cause antipsychotic discontinuation is associated with better schizophrenia treatment outcomes. Biol. Psychiatry 57 (2005) 107S
7. Hamilton S.H., Revicki D.A., Genduso L.A., and Beasley Jr. C.M. Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial. Neuropsychopharmacology 18 1 (1998) 41-49
8. Hamilton S.H., Edgell E.T., Revicki D.A., and Breier A. Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sample. Int. Clin. Psychopharmacol. 15 5 (2000) 245-255
9. Kinon B., et al. Superiority of olanzapine versus quetiapine in improving overall functioning in schizophrenic patients with prominent negative symptoms. Biol. Psychiatry 53 25S (2003) (Suppl. Ref Type: Generic)
10. Kinon B.J., Lipkovich I., Edwards S.B., Ascher-Svanum H., and Siris S.G. A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms. J. Clin. Psychopharmacol. 26 2 (2006) 157-162
11. Lasser R.A., Bossie C.A., Gharabawi G.M., and Kane J.M. Remission in schizophrenia: results from a 1-year study of long-acting risperidone injection. Schizophr. Res. 77 2-3 (2005) 215-227
12. Lieberman J.A., Phillips M., Gu H., Stroup S., Zhang P., Kong L., Ji Z., Koch G., and Hamer R.M. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology 28 5 (2003) 995-1003
13. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353 12 (2005) 1209-1223
14. Liu-Seifert H., Adams D.H., and Kinon B.J. Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Med. 3 (2005) 21
15. Marder S.R., Glynn S.M., Wirshing W.C., Wirshing D.A., Ross D., Widmark C., Mintz J., Liberman R.P., and Blair K.E. Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes. Am. J. Psychiatry 160 8 (2003) 1405-1412
16. Mueser K.T., Douglas M.S., Bellack A.S., and Morrison R.L. Assessment of enduring deficit and negative symptom subtypes in schizophrenia. Schizophr. Bull. 17 4 (1991) 565-582
17. Revicki D.A., Genduso L.A., Hamilton S.H., Ganoczy D., and Beasley Jr. C.M. Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial. Qual. Life Res. 8 5 (1999) 417-426
18. Sethuraman G., Taylor C.C., Enerson M., and Dunayevich E. A retrospective comparison of cumulative time spent in remission during treatment with olanzapine or risperidone among patients with schizophrenia. Schizophr. Res. 79 2-3 (2005) 337-340
19. Tollefson G.D., Beasley Jr. C.M., Tran P.V., Street J.S., Krueger J.A., Tamura R.N., Graffeo K.A., and Thieme M.E. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am. J. Psychiatry 154 4 (1997) 457-465
20. Tran P.V., Hamilton S.H., Kuntz A.J., Potvin J.H., Andersen S.W., Beasley Jr. C., and Tollefson G.D. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J. Clin. Psychopharmacol. 17 5 (1997) 407-418